In 2020, our company made promising progress despite the challenging circumstances caused by the COVID-19 pandemic.

We have been able to establish a more robust platform with more clinical routine customers across all suPARnostic® products and have increased our revenue by 49%.

Our company demonstrated that the European strategy and investments in the commercial efforts are working.

Attachments

  • Original document
  • Permalink

Disclaimer

ViroGates A/S published this content on 24 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 March 2021 15:44:08 UTC.